特发性肺纤维化肺虚络瘀证病证结合生物标志物
|
摘要
特发性肺纤维化(IPF)是一种慢性、进展性疾病,目前缺乏安全、有效的治疗手段,而生物标志物的发现可以协助判断IPF的结局,预测疾病的转归,为诊断和治疗IPF提供了新的思路。文章以IPF肺虚络瘀证为切入点,从分子生物水平对证候进行研究,基于病证结合生物组学的相关研究方法,构建分子生物学调控网络,寻找IPF肺虚络瘀证相关的生物标志物,体现构建病证结合(IPF肺虚络瘀证)生物标志物的价值,从分子水平揭示IPF肺虚络瘀证发病病机、生物学内涵以及病机格局转变。
Idiopathic pulmonary fibrosis(IPF) is a chronic, progressive disease that currently lacks safe and effective treatments, and the discovery of biomarkers can help determine the outcome of IPF and predict the outcome of the disease for diagnosis and treatment. IPF provides a new idea. This article takes idiopathic pulmonary fibrosis and lung deficiency syndrome as the entry point, studies the syndrome from the molecular biological level, and constructs molecular biology based on the relevant research methods of disease syndrome and bionomics. Molecular biological regulation network was constructed to search for biomarkers related to IPF syndrome of lung deficiency and collaterals stasis, which reflected the value of constructing biomarkers combining disease and syndrome(IPF syndrome of lung deficiency and collaterals stasis), and revealed the pathogenesis biological connotation and pathogenesis pattern transformation of IPF syndrome of lung deficiency and collaterals stasis from the molecular level.
Idiopathic pulmonary fibrosis(IPF) is a chronic, progressive disease that currently lacks safe and effective treatments, and the discovery of biomarkers can help determine the outcome of IPF and predict the outcome of the disease for diagnosis and treatment. IPF provides a new idea. This article takes idiopathic pulmonary fibrosis and lung deficiency syndrome as the entry point, studies the syndrome from the molecular biological level, and constructs molecular biology based on the relevant research methods of disease syndrome and bionomics. Molecular biological regulation network was constructed to search for biomarkers related to IPF syndrome of lung deficiency and collaterals stasis, which reflected the value of constructing biomarkers combining disease and syndrome(IPF syndrome of lung deficiency and collaterals stasis), and revealed the pathogenesis biological connotation and pathogenesis pattern transformation of IPF syndrome of lung deficiency and collaterals stasis from the molecular level.
引文
[1]范碧君,蒋捍东.2015版特发性肺纤维化治疗指南解读.医药专论,2016,37(7):453-456
[2]黄云鉴,龚婕宁.中医治疗肺纤维化方药规律的文献分析.中国实验方剂学杂志,2016,22(15):206-210
[3]刘树民,柳长凤,祖金祥,等.基于生物标志物变化的黄芩干预肺热证候研究.中国中药杂志,2011,36(9):1212-1216
[4]王阶,姚魁武,刘咏梅,等.冠心病血瘀证转录组学研究——病证结合生物标志物研究思路与方法.中国实验方剂学杂志,2017,23(19):1-5
[5]刘琳,张云云.对病证结合临床与基础的一些探讨.中国中西医结合杂志,2016,36(8):994-998
[6]Baker M.In biomarkers we trust?.Nature Biotechnology,2005,23(3):297-304
[7]李爱玲,宋健.生物标志物分类及其在临床医学中的应用.中国药理学与毒理学杂志,2015,29(1):7-13,20
[8]石岩,庞立健,刘创,等.基于系统生物学“进化树”中基因探讨特发性肺纤维化治疗新靶标构成.中华中医药杂志,2018,33(4):1516-1519
[9]肖冬媛.i TRAQ技术鉴定百草枯诱导大鼠肺纤维化模型中差异表达蛋白的研究.新乡:新乡医学院,2017
[10]李学任.应用SELDI技术初步筛选肺纤维化生物标记物.石家庄:河北医科大学,2012
[11]刘创,庞立健,吕晓东.基于肺络性能的特发性肺纤维化“肺虚络瘀”病机发微.上海中医药杂志,2014,48(3):28-30
[12]庞立健,臧凝子,王琳琳,等.肺间质纤维化重症病机内涵(肺虚络瘀)初探.中华中医药杂志,2013,28(12):3497-3499
[13]Hambly N,Shimbori C,Kolb M.Molecular classification of idiopathic pulmonary fibrosis:Personalized medicine,genetics and biomarkers.Respirology,2015,20(7):1010-1022
[14]Ley B,Brown K K,Collard H R.Molecular Biomarkers in Idiopathic Pulmonary Fibrosis.American Journal of Physiology Lung Cellular&Molecular Physiology,2014,307(9):1681
[15]Alder J K,Chen J J,Lancaster L,et al.Short telomeres are a risk factor for idiopathic pulmonary fibrosis.Proc Natl Acad Sci USA,2008,105:13051-13056
[16]Seibold M A,Wise A L,Speer M C,et al.A common MUC5B promoter polymorphism and pulmonary fibrosis.N Engl J Med,2011,364:1503-1512
[17]Greene K E,King T E,Kuroki Y,et al.Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis.Eur Respir J,2002,19:439-446
[18]Ohtsuki Y,Fujita J,Hachisuka Y,et al.Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen(EMA)in presumably normal pulmonary tissue and in interstitial pneumonia.Med Mol Morphol,2007,40(4):198-202
[19]Cai M,Bonella F,He X,et al.CCL18 in serum,BAL fluid and alveolar macrophage culture supernatant ininterstitial lung diseases.Respiratory Medicine,2013,107(9):1444-1452
[20]Richards T J,Kaminski N,Baribaud F,et al.Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine,2012,185(1):67-76
[21]刘平,季光,陈凯先.病证结合与中西医结合医学学科知识理论体系的构建.中国中西医结合杂志,2010,30(6):565-570
[22]刘勇明,吕晓东,庞立健,等.肺间质纤维化凝血机制探微.辽宁中医杂志,2016,43(4):880-882
[23]任培中.升陷通络汤对肺纤维化干预作用的实验研究.北京:中国中医科学院,2017
[24]代静泓.中国南京地区汉族人群特发性肺纤维化端粒酶基因突变的遗传学调查.南京:南京大学,2014
[25]宋磊,李丹,竭晶,等.特发性肺纤维化病人血清中SPA的表达及其临床应用价值.中国老年学杂志,2015,35(22):6465-6466
[26]吕晓东,庞立健,刘创.肺络结构和功能与特发性肺纤维化急性发作期“肺热络瘀”病机.世界科学技术-中医药现代化,2014,16(9):1980-1983
[27]陈少贤.特发性肺纤维化急性加重的诊治进展//浙江省医学会.浙江省医学会呼吸系病分会成立三十周年庆典活动暨2008年呼吸病学学术年会论文汇编,2008:4
[28]Collard H R,Calfee C S,Wolters P J,et al.KimPlasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol,299(2010):L3-L7
[29]陈明,曾明,何兴轩.肺纤维化疾病生物标志物的研究进展.中国药理学与毒理学杂志,2017,31(2):187-194
[2]黄云鉴,龚婕宁.中医治疗肺纤维化方药规律的文献分析.中国实验方剂学杂志,2016,22(15):206-210
[3]刘树民,柳长凤,祖金祥,等.基于生物标志物变化的黄芩干预肺热证候研究.中国中药杂志,2011,36(9):1212-1216
[4]王阶,姚魁武,刘咏梅,等.冠心病血瘀证转录组学研究——病证结合生物标志物研究思路与方法.中国实验方剂学杂志,2017,23(19):1-5
[5]刘琳,张云云.对病证结合临床与基础的一些探讨.中国中西医结合杂志,2016,36(8):994-998
[6]Baker M.In biomarkers we trust?.Nature Biotechnology,2005,23(3):297-304
[7]李爱玲,宋健.生物标志物分类及其在临床医学中的应用.中国药理学与毒理学杂志,2015,29(1):7-13,20
[8]石岩,庞立健,刘创,等.基于系统生物学“进化树”中基因探讨特发性肺纤维化治疗新靶标构成.中华中医药杂志,2018,33(4):1516-1519
[9]肖冬媛.i TRAQ技术鉴定百草枯诱导大鼠肺纤维化模型中差异表达蛋白的研究.新乡:新乡医学院,2017
[10]李学任.应用SELDI技术初步筛选肺纤维化生物标记物.石家庄:河北医科大学,2012
[11]刘创,庞立健,吕晓东.基于肺络性能的特发性肺纤维化“肺虚络瘀”病机发微.上海中医药杂志,2014,48(3):28-30
[12]庞立健,臧凝子,王琳琳,等.肺间质纤维化重症病机内涵(肺虚络瘀)初探.中华中医药杂志,2013,28(12):3497-3499
[13]Hambly N,Shimbori C,Kolb M.Molecular classification of idiopathic pulmonary fibrosis:Personalized medicine,genetics and biomarkers.Respirology,2015,20(7):1010-1022
[14]Ley B,Brown K K,Collard H R.Molecular Biomarkers in Idiopathic Pulmonary Fibrosis.American Journal of Physiology Lung Cellular&Molecular Physiology,2014,307(9):1681
[15]Alder J K,Chen J J,Lancaster L,et al.Short telomeres are a risk factor for idiopathic pulmonary fibrosis.Proc Natl Acad Sci USA,2008,105:13051-13056
[16]Seibold M A,Wise A L,Speer M C,et al.A common MUC5B promoter polymorphism and pulmonary fibrosis.N Engl J Med,2011,364:1503-1512
[17]Greene K E,King T E,Kuroki Y,et al.Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis.Eur Respir J,2002,19:439-446
[18]Ohtsuki Y,Fujita J,Hachisuka Y,et al.Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen(EMA)in presumably normal pulmonary tissue and in interstitial pneumonia.Med Mol Morphol,2007,40(4):198-202
[19]Cai M,Bonella F,He X,et al.CCL18 in serum,BAL fluid and alveolar macrophage culture supernatant ininterstitial lung diseases.Respiratory Medicine,2013,107(9):1444-1452
[20]Richards T J,Kaminski N,Baribaud F,et al.Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine,2012,185(1):67-76
[21]刘平,季光,陈凯先.病证结合与中西医结合医学学科知识理论体系的构建.中国中西医结合杂志,2010,30(6):565-570
[22]刘勇明,吕晓东,庞立健,等.肺间质纤维化凝血机制探微.辽宁中医杂志,2016,43(4):880-882
[23]任培中.升陷通络汤对肺纤维化干预作用的实验研究.北京:中国中医科学院,2017
[24]代静泓.中国南京地区汉族人群特发性肺纤维化端粒酶基因突变的遗传学调查.南京:南京大学,2014
[25]宋磊,李丹,竭晶,等.特发性肺纤维化病人血清中SPA的表达及其临床应用价值.中国老年学杂志,2015,35(22):6465-6466
[26]吕晓东,庞立健,刘创.肺络结构和功能与特发性肺纤维化急性发作期“肺热络瘀”病机.世界科学技术-中医药现代化,2014,16(9):1980-1983
[27]陈少贤.特发性肺纤维化急性加重的诊治进展//浙江省医学会.浙江省医学会呼吸系病分会成立三十周年庆典活动暨2008年呼吸病学学术年会论文汇编,2008:4
[28]Collard H R,Calfee C S,Wolters P J,et al.KimPlasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol,299(2010):L3-L7
[29]陈明,曾明,何兴轩.肺纤维化疾病生物标志物的研究进展.中国药理学与毒理学杂志,2017,31(2):187-194